After excluding patients with prior ED, T2D, or confounding pharmacologic treatments, semaglutide use was associated with a higher incidence of newly diagnosed ED or initiation of PDE5 inhibitor therapy (1.47% vs
,
Clinically, this potent effect is demonstrated by agents like semaglutide, which, in phase 2 trials, achieved MASH resolution without worsening fibrosis in a significant percentage of patients (Newsome et al., 2021
GLP 1 & GIP weight loss medications are generally considered safe when used under proper medical guidance
Before starting GLP-1 therapy , patients should discuss their complete medical history with their healthcare provider, including the duration and stability of their Hashimoto's disease, current levothyroxine dose, most recent thyroid function tests, and any family history of thyroid cancer or MEN 2 syndrome